Idorsia Launches Mid-stage Proof-of-concept Trial for Psoriasis Drug Candidate

MT Newswires · 3d ago
01:18 AM EST, 01/06/2026 (MT Newswires) -- Swiss biotech Idorsia (IDIA.SW) launched an exploratory phase 2 proof-of-concept trial to evaluate its psoriasis treatment candidate IDOR1117-2520. The multicenter, double-blind, and randomized trial will assess the efficacy and safety of a selective CCR6 receptor antagonist in adults with moderate-to-severe chronic plaque psoriasis over a period of 12 weeks, according to a Monday release. The trial includes 30 participants, who will receive one of two doses of IDOR-1117-2520 or a placebo once daily. Efficacy will be measured using clinical endpoints such as Psoriasis Area and Severity Index, along with biomarker assessments including beta-defensin 2.